Impact of diabetes against the future risk of developing gout

Objective Although hyperuricaemia and gout are associated with an increased future risk of diabetes, diabetes may reduce the future risk of gout through the uricosuric effect of glycosuria or the impaired inflammatory response. The present work evaluates the impact of diabetes on the future risk of developing gout. Methods A case-control study nested in a UK general practice database (the health improvement network) was conducted by identifying all incident cases of gout (N=24 768) and randomly sampling 50 000 controls who were 20–89 years between 2000 and 2007. The independent effect of type 1 and type 2 diabetes on the development of incident gout was examined. Results After adjusting for age, sex, body mass index, general practitioner visits, smoking, alcohol intake, ischaemic heart disease and presence of cardiovascular risk factors, the RR for incident gout among patients with diabetes, as compared with individuals with no diabetes was 0.67 (95% CI 0.63 to 0.71). The multivariate RRs with the duration of diabetes of 0–3, 4–9 and ≥10 years were 0.81 (95% CI 0.74 to 0.90), 0.67 (95% CI 0.61 to 0.73) and 0.52 (95% CI 0.46 to 0.58), respectively. The inverse association was stronger with type 1 diabetes than with type 2 diabetes (multivariate RR, 0.33 vs 0.69) and stronger among men than women (p value for interaction <0.001). Conclusions Individuals with diabetes are at a lower future risk of gout independent of other risk factors. These data provide support for a substantial role of the pathophysiology associated with diabetes against the risk of developing gout.

[1]  M. Wallander,et al.  Trends in the prevalence and incidence of diabetes in the UK: 1996–2005 , 2009, Journal of Epidemiology & Community Health.

[2]  Hyon K. Choi,et al.  Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. , 2008, Rheumatology.

[3]  Giuseppe Lippi,et al.  High Serum Uric Acid as a Novel Risk Factor for Type 2 Diabetes , 2008, Diabetes Care.

[4]  O. Kano,et al.  GOUT AND RISK OF PARKINSON DISEASE: A PROSPECTIVE STUDY , 2008, Neurology.

[5]  E. Ford,et al.  Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey. , 2008, Rheumatology.

[6]  L. Annemans,et al.  Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005 , 2007, Annals of the rheumatic diseases.

[7]  Hyon K. Choi,et al.  Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease , 2007, Circulation.

[8]  C. Scavone,et al.  Neutrophil function and metabolism in individuals with diabetes mellitus. , 2007, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[9]  Hyon K. Choi,et al.  Prevalence of the metabolic syndrome in individuals with hyperuricemia. , 2007, The American journal of medicine.

[10]  Chaoyang Li,et al.  Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. , 2007, Arthritis and rheumatism.

[11]  P Netter,et al.  EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[12]  P Netter,et al.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[13]  R. Coimbra,et al.  MODULATION OF LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INFLAMMATION: ROLE OF INSULIN , 2006, Shock.

[14]  L. Niskanen,et al.  Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study. , 2006, Diabetes care.

[15]  R. Curi,et al.  Role of insulin on PGE2 generation during LPS-induced lung inflammation in rats. , 2006, Life sciences.

[16]  Hyon K. Choi,et al.  Pathogenesis of Gout , 2005, Annals of Internal Medicine.

[17]  K. Greco,et al.  Lymphatic system changes in diabetes mellitus: role of insulin and hyperglycemia , 2005, Diabetes/metabolism research and reviews.

[18]  W. Bilker,et al.  Gout epidemiology: results from the UK General Practice Research Database, 1990–1999 , 2005, Annals of the rheumatic diseases.

[19]  P. Sannomiya,et al.  Inhibition of leukocyte chemotaxis by serum factor in diabetes mellitus: Selective depression of cell responses mediated by complement-derived chemoattractants , 1990, Agents and Actions.

[20]  A. Bourke,et al.  Feasibility study and methodology to create a quality-evaluated database of primary care data. , 2004, Informatics in primary care.

[21]  M. Martins,et al.  Down-regulation of mast cell activation and airway reactivity in diabetic rats: role of insulin , 2004, European Respiratory Journal.

[22]  Z. Fortes,et al.  Probucol restores the defective leukocyte-endothelial interaction in experimental diabetes. , 2003, European journal of pharmacology.

[23]  A. Fam.  Gout, diet, and the insulin resistance syndrome. , 2002, The Journal of rheumatology.

[24]  P. Chou,et al.  Gender differences in the relationships of serum uric acid with fasting serum insulin and plasma glucose in patients without diabetes. , 2001, The Journal of rheumatology.

[25]  V. Lagente,et al.  Endotoxin-induced acute lung injury in rats. Role of insulin. , 1999, Pulmonary pharmacology & therapeutics.

[26]  B. Emmerson.  Hyperlipidaemia in hyperuricaemia and gout , 1998, Annals of the rheumatic diseases.

[27]  W. Rathmann,et al.  Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. , 1998, Annals of epidemiology.

[28]  H. Jick,et al.  Omeprazole, other antiulcer drugs and newly diagnosed gout. , 2003, British journal of clinical pharmacology.

[29]  P. Vokonas,et al.  Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. , 1995, American journal of epidemiology.

[30]  T. Whitehead,et al.  Serum Urate, Serum Glucose and Diabetes , 1992, Annals of clinical biochemistry.

[31]  Z. Fortes,et al.  Direct Vital Microscopic Study of Defective Leukocyte-Endothelial Interaction in Diabetes Mellitus , 1991, Diabetes.

[32]  H. King,et al.  Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. , 1988, American journal of epidemiology.

[33]  M. Pereira,et al.  Inhibition of Leukocyte Chemotaxis by Factor in Alloxan-Induced Diabetic Rat Plasma , 1987, Diabetes.

[34]  D. Cook,et al.  Serum uric acid, serum glucose and diabetes: relationships in a population study. , 1986, Postgraduate medical journal.

[35]  Z. Fortes,et al.  Vascular reactivity in diabetes mellitus: possible role of insulin on the endothelial cell , 1984, British journal of pharmacology.

[36]  Z. Fortes,et al.  Vascular reactivity in diabetes mellitus: role of the endothelial cell , 1983, British journal of pharmacology.

[37]  U. Goldbourt,et al.  URIC ACID AND DIABETES: OBSERVATIONS IN A POPULATION STUDY , 1982, The Lancet.

[38]  G. Böhm,et al.  Decreased vascular reactions to permeability factors in experimental diabetes. , 1976, British journal of experimental pathology.

[39]  G. Böhm,et al.  Possible participation of insulin in the control of vascular permeability. , 1974, European journal of pharmacology.

[40]  M. Silva,et al.  Pharmacological analysis of the acute inflammatory process induced in the rat's paw by local injection of carrageenin and by heating , 1973, British journal of pharmacology.